News & Resources
Resources
Curapath Strengthens Partnership in Breakthrough Genetic Medicine with Multiyear Development and Manufacturing Agreement
BOSTON and VALENCIA, Feb. 14, 2024 – Curapath, a leader in the development and custom manufacturing of polymer- and lipid-based delivery systems for advanced therapies,
Curapath Appoints Philippe Clavel as Chief Executive Officer
Curapath, a developer, manufacturer, and formulator of lipid- and polymer-based nanoparticles used in advanced therapeutic delivery technology, today announced the appointment of Philippe Clavel as Chief Executive
Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products
Valencia, Spain and Boston, MA, January 26, 2023 – Curapath, a leader in the design, development, andcustom manufacturing of polyamino-acid- and lipid nanoparticle (LNP) delivery
Curapath Announces Collaboration with Afrigen Biologics to Advance Development of African-owned mRNA SARS-CoV-2 Vaccine
Curapath will develop and optimize a process to produce a nanoparticle formulation for the vaccine Valencia, Spain and Boston, MA, November 16, 2022 – Curapath,
Polypeptide Therapeutics Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services
Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned
